VEGFA and Thromboembolism: The proangiogenic effect of dalteparin in the present report should be beneficial for the treatment of non-cancer patients with poor peripheral circulation or thromboembolism causing tissue hypoxia, which induces compensatory VEGF-mediated angiogenesis.